Unknown

Dataset Information

0

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.


ABSTRACT: This was a double-blind, randomized, controlled, phase II clinical trial, two dose study of re-derived, live-attenuated, tetravalent dengue virus (TDEN) vaccine (two formulations) or placebo in subjects 1-50 years of age. Among the 636 subjects enrolled, 331 (52%) were primed, that is, baseline seropositive to at least one dengue virus (DENV) type. Baseline seropositivity prevalence increased with age (10% [< 2 years], 26% [2-4 years], 60% [5-20 years], and 93% [21-50 years]). Safety profiles of TDEN vaccines were similar to placebo regardless of priming status. No vaccine-related serious adverse events (SAEs) were reported. Among unprimed subjects, immunogenicity (geometric mean antibody titers [GMT] and seropositivity rates) for each DENV increased substantially in both TDEN vaccine groups with at least 74.6% seropositive for four DENV types. The TDEN vaccine candidate showed an acceptable safety and immunogenicity profile in children and adults ranging from 1 to 50 years of age, regardless of priming status. ClinicalTrials.gov: NCT00468858.

SUBMITTER: Bauer K 

PROVIDER: S-EPMC4559678 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.

Bauer Kristen K   Esquilin Ines O IO   Cornier Alberto Santiago AS   Thomas Stephen J SJ   Quintero Del Rio Ana I AI   Bertran-Pasarell Jorge J   Morales Ramirez Javier O JO   Diaz Clemente C   Carlo Simon S   Eckels Kenneth H KH   Tournay Elodie E   Toussaint Jean-Francois JF   De La Barrera Rafael R   Fernandez Stefan S   Lyons Arthur A   Sun Wellington W   Innis Bruce L BL  

The American journal of tropical medicine and hygiene 20150714 3


This was a double-blind, randomized, controlled, phase II clinical trial, two dose study of re-derived, live-attenuated, tetravalent dengue virus (TDEN) vaccine (two formulations) or placebo in subjects 1-50 years of age. Among the 636 subjects enrolled, 331 (52%) were primed, that is, baseline seropositive to at least one dengue virus (DENV) type. Baseline seropositivity prevalence increased with age (10% [< 2 years], 26% [2-4 years], 60% [5-20 years], and 93% [21-50 years]). Safety profiles of  ...[more]

Similar Datasets

| S-EPMC4080550 | biostudies-literature
| S-EPMC5953365 | biostudies-literature
| S-EPMC4889756 | biostudies-literature
2021-01-21 | E-MTAB-9385 | biostudies-arrayexpress
| S-EPMC8341694 | biostudies-literature
| S-EPMC4768757 | biostudies-literature
| S-EPMC2669169 | biostudies-other
| S-EPMC4648257 | biostudies-literature
| S-EPMC8892502 | biostudies-literature
| S-EPMC4634119 | biostudies-other